• 1
    Ward C, Tudor-Williams G, Cotzias T, Hargreaves S, Regan L, Foster GR. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut 2000;47(2):277280.
  • 2
    Floreani A, Paternoster D, Zappala F, et al. Hepatitis C virus infection in pregnancy. Br J Obstet Gynaecol 1996;103(4):325329.
  • 3
    Pipan C, Amici S, Astori G, Ceci GP, Botta GA. Vertical transmission of hepatitis C virus in low-risk pregnant women. Eur J Clin Microbiol Infect Dis 1996;15(2):116120.
  • 4
    Tong M, El-Farrah N, Reikes A, Co R. Clinical outcomes after transfusion associated hepatitis C virus. N Engl J Med 1995;332: 14631466.
  • 5
    Manns M, McHutchinson J, et al. Peginterferon alfa 2b plus ribavirin compared to interferon alfa 2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicentre, multinational phase III randomized controlled trial. Dallas , USA : AASLD, 2000.
  • 6
    Fried M, Shiffman M, Reddy R, et al. Pegylated (40 kDa) interferon Alfa-2a (PEGASYS*) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Atlanta , USA : DDW, 2001.